Search

Now showing items 1-7 of 7

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects

Karanikas, V.; Zamanakou, M.; Soukou, F.; Kerenidi, T.; Tsougos, I.; Theodorou, K.; Georgoulias, P.; Gourgoulianis, K. I.; Germenis, A. E. (2010)

Background: This study aimed to examine whether EBV seropositive patients with lung cancer have an altered virus-specific CTL response, as compared to age-matched healthy controls and whether any variation in this response ...

Anti-survivin antibody responses in lung cancer

Karanikas, V.; Khalil, S.; Kerenidi, T.; Gourgoulianis, K. I.; Germenis, A. E. (2009)

Existing evidence regarding spontaneous anti-survivin humoral responses in lung cancer is inconclusive. Moreover, despite that cancer cell death elicited by radiotherapy and some chemotherapeutic agents seems to be ...

Indoleamine 2,3-dioxygenose (IDO) expression in lung cancer

Karanikas, V.; Zamanakou, M.; Kerenid, T.; Dahabreh, J.; Hevas, A.; Nakou, M.; Gourgoulianis, K. I.; Germenis, A. E. (2007)

Background: The expression of indoleamine 2,3-dioxygenase (IDO) by tumor cells has been considered as a major tumor immune escape mechanism. The aim of this study was to investigate the expression of IDO in lung cancer ...

Foxp3 expression in human cancer cells

Karanikas, V.; Speletas, M.; Zamanakou, M.; Kalala, F.; Loules, G.; Kerenidi, T.; Barda, A. K.; Gourgoulianis, K. I.; Germenis, A. E. (2008)

Objective: Transcription factor forkhead box protein 3 (Foxp3) specifically characterizes the thymically derived naturally occurring regulatory T cells (Tregs). Limited evidence indicates that it is also expressed, albeit ...

Naturally occurring tumor-specific CD8(+) T-cell precursors in individuals with and without cancer

Karanikas, V.; Zamanakou, M.; Soukou, F.; Kerenidi, T.; Gourgoulianis, K. I.; Germenis, A. E. (2010)

Boosting pre-existing, naturally occurring cytolytic CD8(+) T-cell (CTLs) responses directed against class-I MHC-restricted peptides of tumor antigens, represents a primary goal of cancer immunotherapy. The number of ...

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer

Karanikas, V.; Zamanakou, M.; Kerenidi, T.; Dahabreh, J.; Hevas, A.; Nakou, M.; Gourgoulianis, K. I.; Germenis, A. E. (2007)

Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals

Karanikas, V.; Soukou, F.; Kalala, F.; Kerenidi, T.; Grammoustianou, E. S.; Gourgoulianis, K. I.; Germenis, A. E. (2008)

Survivin and its variant survivin-2B have been considered as potential candidates for cancer immunotherapy. The magnitude however of spontaneously occurring CD8+ T cells circulating precursor CTLs (pCTL), has never been ...